28.07 05:23 | dpa-AFX: Astellas: Zolbetuximab Combo Gets Positive CHMP Opinion In Advanced Gastric &Gastroesophageal Cancer |
22.07 07:50 | dpa-AFX: Astellas, Osaka University To Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy |
22.07 07:41 | dpa-AFX: *ASTELLAS PHARMA, OSAKA UNIVERSITY COLLABORATE TO DEVELOP PLURIPOTENT STEM CELL-DERIVED CARTILAGE ORGANOID CELL THERAPY |
31.05 05:07 | dpa-AFX: FDA Acknowledges Astellas Pharma's Resubmission Of BLA For Zolbetuximab |
02.05 04:04 | dpa-AFX: Astellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In Oncology |
26.04 09:58 | MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus |
25.04 12:51 | dpa-AFX: Astellas Pharma Annual Net Plunges, But Revenue Climbs; Expects 2024 Result To Improve |
25.04 11:13 | dpa-AFX: *ASTELLAS PHARMA FY REVENUE UP 5.6% TO 1.60 TRLN YEN |
24.04 02:57 | dpa-AFX: European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment |
24.04 02:29 | dpa-AFX: *EUROPEAN COMMISSION APPROVES ASTELLAS' XTANDI FOR RECURRENT EARLY PROSTATE CANCER TREATMENT EXPANSION |
22.04 11:12 | dpa-AFX: Takeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery Programs |
22.04 10:13 | dpa-AFX: *TAKEDA, ASTELLAS AND SUMITOMO MITSUI BANKING ANNOUNCE MASTER AGREEMENT TO ESTABLISH JOINT VENTURE COMPANY |
15.04 09:23 | MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg |
28.03 17:07 | dpa-AFX: Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China |
28.03 16:02 | dpa-AFX: *CHINA ACCEPTS ASTELLAS AND PFIZER'S SBLA FOR ENFORTUMAB VEDOTIN WITH KEYTRUDA FOR TREATMENT OF ADVANCED BLADDER CANCER |
26.03 13:47 | dpa-AFX: Astellas' Vyloy Approved In Japan For Gastric Cancer |
26.03 13:03 | dpa-AFX: *ASTELLAS' VYLOY APPROVED IN JAPAN FOR GASTRIC CANCER TREATMENT |
22.03 13:39 | dpa-AFX: Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting |
22.03 13:01 | dpa-AFX: *ASTELLAS GETS POSITIVE CHMP OPINION FOR XTANDI IN ADDL RECURRENT EARLY PROSTATE CANCER TREATMENT SETTING |
11.03 15:23 | dpa-AFX: Astellas Receives FDA Orphan Drug, Pediatric Exclusivities For Cresemba |
|